Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
4
×
national blog main
boston blog main
boston top stories
clinical trials
national top stories
san francisco blog main
san francisco top stories
biotech
data
new york blog main
new york top stories
accelerated approval
acute hepatic porphyria
alnylam pharmaceuticals
amgen
aminolevulinic acid
boston
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
cancer
cancer immunotherapy
cancer vaccine
cholesterol
chronic kidney disease
clinical study
detroit blog main
detroit top stories
disease
drugs
enzyme
fda
food and drug administration
forty seven
gag
gene editing
genome editing
givosiran
hunter syndrome
What
nasdaq
4
×
medicine
drug
new
therapeutics
week
aces
alnylam
announced
benefit
big
biotechs
ceo
cholesterol
cleared
club
companies
continued
crop
data
editing
exceeded
far
firms
flexible
gene
going
group
haul
humans
inclisiran
interference
ipo
isn't
joined
key
landmark
latest
life
little
Language
unset
Current search:
nasdaq
×
" life sciences "
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M